Oliver Lomas

Bleximenib in Combination with Intensive Chemotherapy: A phase 1b Study in Patients with Newly Diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 Alterations

Hartmut Döhner, Andre C. Schuh, Christian Recher, Jenny O’Nions et autres

Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Hartmut Döhner, Andre C. Schuh, Christian Récher, Jenny O’Nions et autres

Abstract Objective Bleximenib is a potent, selective menin inhibitor with activity in NPM1-mutated (NPM1m)or KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML), now in Phase 3 development in combination with AML-directed therapies. Previous data have shown an acceptable safety and efficacy profile in participants …

de, ca, fr, gb, us, es, it, au (code pays fourni par la source)

Phase 1b study of bleximenib in combination with venetoclax in Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Jenny O’Nions, Andrew H. Wei, Jordi Esteve, Ibrahim Aldoss et autres

Abstract Objective Bleximenib is a potent, selective menin inhibitor with activity in NPM1-mutated (NPM1m)or KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML), now in Phase 3 development in combination with AML-directed therapies. Phase 1 data with bleximenib 100 mg twice daily (BID) dose in …

gb, au, es, us, fr, it, de (code pays fourni par la source)

POSTER: AML-388 Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination With Intensive Chemotherapy (IC) in Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) with KMT2Ar or NPM1 Alterations

Elias Jabbour, Christian Récher, Jenny O’Nions, Ibrahim Aldoss et autres

AML-388: Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination With Intensive Chemotherapy (IC) in Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) with KMT2Ar or NPM1 Alterations

Elias Jabbour, Christian Récher, Jenny O’Nions, Ibrahim Aldoss et autres

us, fr, gb, es, be, it, de, au (code pays fourni par la source)

AML-418: Recommended Phase 2 Dose (RP2D) Determination of Bleximenib in Combination With Venetoclax+Azacitidine (VEN+AZA): Phase Ib Study in Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) With KMT2A or NPM1 Alterations

Andrew H. Wei, Sylvain Garciaz, Ibrahim Aldoss, Ana Alfonso Piérola et autres

POSTER: AML-418 Recommended Phase 2 Dose (RP2D) Determination of Bleximenib in Combination With Venetoclax+Azacitidine (VEN+AZA): Phase Ib Study in Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) With KMT2A or NPM1 Alterations

Andrew H. Wei, Jordi Esteve, Sylvain Garciaz, Ibrahim Aldoss et autres

au, es, fr, us, it, de, br, gb (code pays fourni par la source)

The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study

Anna Santarsieri, Emily Mitchell, My H. Pham, Rashesh Sanghvi et autres

BACKGROUND: Procarbazine-containing chemotherapy regimens are associated with cytopenias and infertility, suggesting stem-cell toxicity. When treating Hodgkin lymphoma, procarbazine in escalated-dose bleomycin-etoposide-doxorubicin-cyclophosphamide-vincristine-procarbazine-prednisolone (eBEACOPP) is increasingly replaced with dacarbazine (eBEACOPDac) to reduce toxicity. We aimed to investigate the impact of this drug substitution on …

gb, de, fr (code pays fourni par la source)

Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial

Lise J Estcourt, Zoe McQuilten, Peter Bardy, Merrole Cole‐Sinclair et autres

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Christian Récher, Jenny O’Nions, Ibrahim Aldoss, Ana Alfonso Piérola et autres

Background: Newly diagnosed (ND) acute myeloid leukemia (AML) is a genetically heterogeneous disease with a median 5-year overall survival of approximately 30%. Combining standard intensive chemotherapy (IC) approaches with targeted therapies may further improve outcomes. Bleximenib is a potent, selective menin-KMT2A complex …

fr, gb, us, es, it, de, au, be (code pays fourni par la source)

Procarbazine-induced Genomic Toxicity in Hodgkin Lymphoma Survivors

Anna Santarsieri, Emily Mitchell, My H. Pham, Rashesh Sanghvi et autres

Abstract Background Procarbazine-containing chemotherapy regimens associate with cytopenias and infertility, suggesting stem cell toxicity. Procarbazine in eBEACOPP (escalated dose bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisolone) is increasingly replaced with dacarbazine (eBEACOPDac) to reduce toxicity, although limited genomic and clinical data support …

gb, de, pt, fr, ru (code pays fourni par la source)

Discovery of JNJ-88549968, a Novel, First-in-Class CALRmutxCD3 T-Cell Redirecting Antibody for the Treatment of Myeloproliferative Neoplasms

Anna Kuchnio, Elsie Samakai, Eva Hug, Meritxell Balmaña et autres

Myeloproliferative neoplasms (MPNs) are clonal malignant disorders of hematopoiesis arising in the hematopoietic stem cell (HSC) compartment that are characterized by excessive production of mature blood cells of the myeloid lineage. Transformation to secondary acute myeloid leukemia (sAML) represents a significant cause …

be, us, gb, at (code pays fourni par la source)